FANCD2
Chr 3ARFA complementation group D2
Also known as: FA-D2, FA4, FACD, FAD, FAD2, FANCD
FANCD2 encodes a protein essential for DNA repair through homologous recombination and maintenance of chromosomal stability, particularly during replication stress and meiosis. Mutations cause Fanconi anemia complementation group D2, an autosomal recessive disorder characterized by bone marrow failure, increased cancer risk, and developmental abnormalities. This gene shows minimal constraint against loss-of-function variants in the general population, consistent with its recessive inheritance pattern.
Definitive — sufficient evidence for diagnostic panels
Population Genetics & Constraint
gnomAD v4 — loss-of-function & missense intolerance
Typical tolerance to LoF variation
Mild missense constraint
ClinVar Variant Classifications
500 submitted variants in ClinVar
Classification Summary
Curated Variants Distribution
Classified variants from ClinVar · 5 ACMG categories
| Classification | LoF | Missense + Inframe | Non-coding | Synonymous | Total |
|---|---|---|---|---|---|
Pathogenic | 20 | 0 | 22 | 0 | 42 |
Likely Pathogenic | 41 | 0 | 2 | 0 | 43 |
VUS | 1 | 212 | 22 | 8 | 243 |
Likely Benign | 0 | 0 | 70 | 69 | 139 |
Benign | 1 | 0 | 1 | 0 | 2 |
Conflicting | — | 1 | |||
| Total | 63 | 212 | 117 | 77 | 470 |
LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly
View in ClinVar →Protein Context — Lollipop Plot
FANCD2 · protein map & ClinVar variants
Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.
3D Protein StructureAlphaFold
External Resources
Links to major genomics databases and tools
Clinical Trials
Active and recruiting trials from ClinicalTrials.gov
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
RECRUITINGPrevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History
NOT YET RECRUITINGSerial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
RECRUITINGNiraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
ACTIVE NOT RECRUITINGExternal Resources
Links to major genomics databases and tools